51 research outputs found
Ética e Investigación Científica en la Sociedad Globalizada
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0370-41062009000400001&nrm=is
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
Background: Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods: The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings: We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation: Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding: Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health
A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study
Background: Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care unit (NICU) may inform antimicrobial stewardship efforts. Methods: We conducted a one-day global point prevalence study of all antimicrobials provided to NICU infants. Demographic, clinical, and microbiologic data were obtained including NICU level, census, birth weight, gestational/chronologic age, diagnoses, antimicrobial therapy (reason for use; length of therapy), antimicrobial stewardship program (ASP), and 30-day in-hospital mortality. Findings: On July 1, 2019, 26 of infants (580/2,265; range, 0�100; median gestational age, 33 weeks; median birth weight, 1800 g) in 84 NICUs (51, high-income; 33, low-to-middle income) from 29 countries (14, high-income; 15, low-to-middle income) in five continents received �1 antimicrobial agent (92, antibacterial; 19, antifungal; 4, antiviral). The most common reasons for antibiotic therapy were �rule-out� sepsis (32) and �culture-negative� sepsis (16) with ampicillin (40), gentamicin (35), amikacin (19), vancomycin (15), and meropenem (9) used most frequently. For definitive treatment of presumed/confirmed infection, vancomycin (26), amikacin (20), and meropenem (16) were the most prescribed agents. Length of therapy for culture-positive and �culture-negative� infections was 12 days (median; IQR, 8�14) and 7 days (median; IQR, 5�10), respectively. Mortality was 6 (42, infection-related). An NICU ASP was associated with lower rate of antibiotic utilization (p = 0·02). Interpretation: Global NICU antibiotic use was frequent and prolonged regardless of culture results. NICU-specific ASPs were associated with lower antibiotic utilization rates, suggesting the need for their implementation worldwide. Funding: Merck & Co.; The Ohio State University College of Medicine Barnes Medical Student Research Scholarship © 2021 The Author
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health
Soil thermal response under plastic covers II. Effect of transparent polyethylene at different depths
During November of 1996, an experiment was carried out at the
Universidad Católica del Maule, Talca (35º26' S lat,
71º26' W long.) in a Haplanthrepts soil, to determine the soil
thermal response under a transparent polyethylene cover (50 m ) at 1,
3, 7 and 15 cm depth, as well as the transversal thermal response
(phases 2, 3 and 5). In phases 1 and 4, the effect of four plastic
covers on the soil temperature at 7cm depth was informed in a previous
paper. Tukey s test was applied (p £ 0.05) to the thermal
amplitude in order to verify the reliability of the results. Its value
increased about 10°C up to 7 cm depth, showing that it is possible
to solarize at this latitude, with a mean temperature of 36°C at 7
cm depth, and with possibly lethal maximums at depths of 7 to 15 cm
after 15 days treatment. Phase 5 revealed that there is a thermal
decrease toward the borders of the film cover, showing a central area
of 20-30 cm where the temperature is uniform. The information obtained
is useful to verify a model that describes the thermal conduct of soil
under a plastic cover
Soil thermal response under plastic covers III. Simulation
A simplified simulation model was developed to predict soil temperature
under plastic covers based on the numerical solution of the soil heat
flow equation. This method requires the definition of the boundary
conditions, which at the soil surface are solved through the radiation
and energy balance. Also it considers the heat partitioning ratio and
the albedo of the soil surface covered with plastic film. This
parameter is variable according to the time of the day. Thus the soil
surface temperature was estimated and treated as if it were identical
to the temperature of the plastic. To start the simulation process and
to determine the soil profile temperature, a periodic function
combining the analytical solution and a Fourier analysis with four
elements (k = 4) was used. The temperature at 30 cm depth was
considered constant for the model scale, which was experimentally
confirmed. A computer program was elaborated that would operate at
different time lapses and depth spacing according to soil thermal
diffusivity. The assumption that plastic sheet was in direct contact
with soil surface led to acceptable agreement between simulated and
experimental results. However, it was also necessary to modify the
values of surface emissivity and this remains a point needing further
elucidation
Comportamiento térmico del suelo bajo cubiertas plásticas. I: efecto de diferentes tipos de láminas.
Durante noviembre de 1996 se realizó un experimento en la Universidad Católica del Maule, Talca (35º26¿ lat. Sur, 71º26¿ long. Oeste), en un suelo Haplanthrepts, para determinar la conducta térmica del suelo bajo cuatro cubiertas plásticas diferentes a 7 cm de profundidad: polietileno transparente (TRA), film blanco/negro (OPA), film AL-OR, café (CAF) y polietileno naranja (NAR). Se seleccionaron las láminas TRA y OPA por ser opuestas en transmisividad, NAR y CAF, como alternativas de acolchados (mulch) ofrecidas en el mercado. TRA alcanzó la temperatura más alta (máxima promedio = 39,1°C), acumulando más calor que CAF y produciendo ambos tratamientos incrementos térmicos superiores a OPA, que mantuvo el suelo ligeramente por debajo de la temperatura del suelo descubierto (máxima promedio = 27,3°C), aunque esta diferencia no resultó significativa (Tukey 5%). La menor temperatura acumulada por OPA mostró una compensación nocturna, con una temperatura mínima más alta que el suelo descubierto. CAF no acusó diferencia con NAR, lo que reveló que sus ventajas no se relacionan con el incremento térmico del suelo. De acuerdo con el alza térmica mostrada por TRA sería posible solarizar en esta latitud, obteniendo temperaturas máximas posiblemente letales para los organismos mesotérmicos después de 15 días de tratamiento en noviembre, con 6 horas diarias sobre 40°C. Según los resultados observados, es posible asegurar que la utilización actual de cubiertas plásticas en Chile es deficiente y, a veces, hasta contradictoria con el objetivo propuesto. La información obtenida es de utilidad para verificar un modelo que describa la conducta térmica del suelo bajo una cubierta plástica
- …